Hipril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hipril

This foundational section defines the medicine Hipril by its composition, type, origin, and general function, strictly avoiding details related to dosages, specific treatments, usage instructions, or safety information.

Property Description
Active ingredient Lisinopril
Form Oral solid dosage (Tablets)
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose Management of systemic blood pressure
Origin Synthetic

What is Hipril and What Type of Medicine is Lisinopril?

Hipril is a prescription-only brand name for a single-ingredient medicine whose active substance is Lisinopril. It is formally classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, representing a foundational class of drugs whose efficacy is clinically recognized for managing cardiovascular conditions. Lisinopril belongs to the broader group of antihypertensive agents, meaning its primary role is to counter conditions associated with elevated systemic vascular pressure. Lisinopril is established as a drug that promotes the widening of blood vessels. This classification reflects the medicine's role in supporting circulatory health through vascular relaxation.


Composition, Origin, and Form

The active core of Hipril is the compound Lisinopril, which is supplied as an oral solid dosage form, specifically manufactured as tablets. Lisinopril is a synthetic molecule, meaning it is chemically synthesized rather than being naturally derived. Unlike some other cardiovascular agents that may require complex formulations, Lisinopril is known for its relatively straightforward chemical structure, which is reflected in its standard tablet formulation. Lisinopril acts by preventing the formation of angiotensin II, a chemical that constricts blood vessels. This mechanism is key to the medicine's systemic and predictable action upon oral administration.


General Purpose and Cardiovascular Role

The general purpose of this medication is to support the cardiovascular system by managing the pressure exerted on the arteries. Lisinopril achieves this by promoting the relaxation and widening of blood vessels, a mechanism that is a cornerstone of modern antihypertensive therapy. By reducing the overall resistance in the circulatory system, the medicine effectively decreases the workload required of the heart to pump blood, which is the overall benefit derived from its use as an ACE inhibitor for the sustained management of high blood pressure.

What side effects are possible with Hipril?

Possible side effects and safety information

The official safety profile for Hipril (Lisinopril) is structured by government regulatory agencies, such as the FDA and EMA, to classify adverse reactions based on frequency and the body system affected.


Frequency-Classified Adverse Reactions

Adverse reactions that are frequently observed in regulatory data are formally classified. Common (expected in ge 1% to <10% of patients) effects typically include headache, dizziness, a persistent dry cough, and fatigue. Reactions classified as Uncommon or Rare include events such as rash, nausea, vomiting, or significant drops in blood pressure (hypotension).


Serious Adverse Reactions and Safety Constraints

The most serious events documented in official labeling include Angioedema (swelling of the face, lips, tongue, and throat), severe Symptomatic Hypotension (which may lead to secondary cardiovascular events), and Acute Renal Failure.

Safety constraints and contraindications are explicitly defined: Hipril is prohibited during the second and third trimesters of pregnancy due to regulatory evidence of fetal toxicity and death. Use is also contraindicated in patients with a history of Angioedema related to any previous ACE inhibitor or in patients with diabetes or renal impairment taking Aliskiren.


Population and Timing Notes

The regulatory profile notes that a significant drop in blood pressure (hypotension) is most likely to occur at the initiation of therapy or immediately following a dose adjustment. Caution is required for patients with pre-existing renal impairment or those who are volume-depleted, as these groups carry a higher risk of developing progressive kidney issues and electrolyte imbalances like Hyperkalemia (high blood potassium) according to official labeling.

Overdose and Emergency Response

The official regulatory profile for a Hipril (Lisinopril) overdose is defined by the risk of profound pharmacological effects, primarily manifesting as cardiovascular instability. The critical toxic effect is severe hypotension (extremely low blood pressure), which may progress to circulatory shock. Other documented manifestations include cardiac irregularities such as tachycardia or bradycardia, and CNS findings like dizziness and anxiety. Severe overdose is also associated with significant electrolyte disturbances, specifically hyperkalaemia (high potassium) and hyponatraemia (low sodium).

Severe overdose is linked to life-threatening outcomes, including acute renal failure and the potential for secondary events such as Myocardial Infarction or Cerebrovascular Accident resulting from prolonged, excessive hypotension.

Severe Overdose Outcomes Documented Monitoring and Management Measures
Acute Renal Failure Intravenous saline infusion for hypotension.
Circulatory Shock Drug removal via haemodialysis.
Secondary Vascular Events (MI or CVA) Minimum four hours observation for asymptomatic patients.

There is no specific pharmacological antidote documented for Lisinopril overdose. Management is symptomatic and supportive. Regulatory authorities mandate that immediate medical attention must be sought if signs of severe overdose occur, explicitly stating the need to contact emergency services for collapse, seizure, trouble breathing, or inability to be awakened. Symptomatic or hypotensive patients require admission for at least 24 hours with continuous monitoring.

Therapeutic Uses of Hipril

What Hipril Treats: Main Uses and Benefits

Hipril is a medication used to help manage cardiovascular conditions and their associated symptoms. The core therapeutic uses are centered on managing conditions presenting with systemic or localized discomfort. Hipril is used for the treatment of hypertension, as adjunctive therapy for heart failure, and for use in therapeutic support following an acute myocardial infarction.

This medicine is commonly used across conditions presenting with acute episodes and chronic situations where patients experience symptoms related to heightened physiological activity. It is applied across domains where additional symptomatic support is needed, particularly for conditions characterized by periods of heightened symptoms.


Key Symptomatic Support

Hipril plays a role in managing symptoms that create noticeable functional strain and is relevant in clinical settings that involve acute or unstable symptom patterns. It is used in areas where short-term symptom management is appropriate, often during phases when symptoms become more noticeable. This application supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load.

“It is applied when symptoms interfere with daily comfort and require supportive relief.”

Quick Note: Support for Symptomatic Periods Hipril may assist with maintaining functional stability when symptoms related to systemic imbalance are more noticeable.

Eligibility and Restrictions for Use

Hipril (Lisinopril) is subject to strict eligibility rules defined in official regulatory documents. Eligibility is determined by age, pre-existing conditions, and physiological states, restricting who may use the medicine.

Contraindicated Populations (Absolute Non-Eligibility)
Patients with a history of angioedema related to any ACE Inhibitor.
Patients with hereditary or idiopathic angioedema.
Pregnant women, particularly during the second and third trimesters.
Patients taking a neprilysin inhibitor (e.g., sacubitril/valsartan) or within 36 hours of stopping one.
Patients with diabetes mellitus who are concurrently taking aliskiren (a direct renin inhibitor).
Age-Related Eligibility Rules
Approved Use: Established for adults and for pediatric patients ge 6 years of age for hypertension only.
Use Not Recommended/Established: Not recommended for children under 6 years of age as safety and efficacy have not been established.
Older Adults: No specific restriction, but close monitoring is advised due to the higher likelihood of age-related renal function decline.
Condition-Specific Eligibility Restrictions
Renal Impairment: Requires restricted use, especially in patients with creatinine clearance le 30 mL/min.
Volume/Salt Depletion: Use requires caution and often a lower starting dose to manage the risk of significant hypotension.
Lactation: Use is generally not recommended due to insufficient data on excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Hipril (Lisinopril) are primarily defined by pharmacodynamic effects on blood pressure and electrolyte balance, along with specific timing restrictions for certain prohibited combinations.


Contraindicated Combinations and Restrictions

Co-administration with Sacubitril/Valsartan is strictly contraindicated. A 36-hour separation period is mandated after the last dose of Sacubitril/Valsartan before initiating Lisinopril. Use with Aliskiren is also contraindicated in patients with diabetes mellitus or existing renal impairment (GFR <60 mL/min/1.73 m^2).


Pharmacodynamic and Exposure-Altering Interactions

Lisinopril's interaction profile involves substances that affect potassium levels or have an additive blood pressure-lowering effect. Combining Lisinopril with Potassium-sparing diuretics, Potassium supplements, or salt substitutes that contain potassium increases the risk of Hyperkalemia (elevated serum potassium). Co-administration with Diuretics or other antihypertensive agents may result in a significant additive antihypertensive effect leading to excessive blood pressure reduction. Co-administration with mTOR Inhibitors (e.g., Sirolimus) or Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is documented to increase the risk of severe swelling (Angioedema) or worsening renal function, respectively. Lisinopril is also documented to reduce the renal clearance of Lithium, which can result in increased Lithium concentrations and potential toxicity. Lisinopril absorption is not influenced by food.

Mechanism of Action

The mechanism of Lisinopril involves the modulation of the Renin-Angiotensin-Aldosterone System (RAAS) and related vascular pathways. The drug's action is defined by a precise biochemical intervention that shifts the balance of powerful regulatory molecules within the circulatory system.

The core mechanism involves the specific inhibition of the Angiotensin-Converting Enzyme (ACE), a zinc-dependent enzyme primarily found in the blood vessel lining. By binding to and blocking ACE, Lisinopril prevents the conversion of Angiotensin I into the potent vasoconstrictor, Angiotensin II. This molecular intervention dampens the activity of the RAAS cascade, which is critical for regulating systemic fluid and vascular tone.

The blockade of ACE creates a dual physiological effect on the blood vessels. First, the reduction in Angiotensin II removes the primary stimulus for vascular smooth muscle contraction. Second, the drug simultaneously slows the breakdown of the natural vasodilator Bradykinin, leading to its accumulation. The combined effect of reduced vasoconstrictive signals and enhanced vasodilation (through Bradykinin) results in a reduction in the overall Systemic Vascular Resistance (SVR), alongside a subsequent decrease in Aldosterone secretion that affects fluid and electrolyte homeostasis.

The drug's mechanism is specifically limited to the ACE pathway. In some biological contexts, Angiotensin II can be produced through non-ACE enzymes like Chymase, which are unaffected by the drug. This ACE escape mechanism represents a physiological constraint that may limit the maximum achievable suppression of Angiotensin II signaling, thereby determining the maximum extent of RAAS suppression achieved by the mechanism.

Dosage and Administration Information

Official Administration Guidelines for Hipril

Hipril is for oral administration and is supplied as an immediate-release tablet. The medicine is for once daily (QD) administration. To maintain consistent systemic levels, the tablet should be taken at approximately the same time each day but may be consumed with or without food.

The protocol for use involves initiating therapy with a low, condition-specific starting dose, followed by a systematic process of gradual dose adjustment (titration). For instance, the starting dose for hypertension is commonly 10 mg or 20 mg, with a subsequent adjustment period to reach the long-term maintenance range, which often falls between 20 mg and 40 mg.

Specific adjustments are required for certain populations. The starting dose is lowered for adult patients with confirmed renal impairment (creatinine clearance le 30 mL/min). If a scheduled dose is missed, the procedural instruction is to skip the missed dose entirely and resume the regular schedule the following day, as doubling the next dose is not recommended. This structured approach governs the consistent administration of the medication as a sustained, long-term therapeutic plan.

Recent Clinical Evidence

Hipril (an Angiotensin-Converting Enzyme, or ACE inhibitor) is a widely studied class of medication primarily used for managing high blood pressure (hypertension) and heart failure. Research continues to explore its role, particularly regarding optimal blood pressure targets and combination therapies.

Clinical Outcomes in Hypertension

Studies have consistently demonstrated that lowering elevated blood pressure (BP) is associated with a reduction in the risk of major cardiovascular events such as heart attack, heart failure, and stroke. Recent large, randomized trials have focused on defining the most beneficial target for systolic blood pressure (SBP), with some evidence suggesting greater benefits when aiming for a lower SBP (e.g., below 130 mmHg) in high-risk patients, compared to previous standard targets.

Role in Heart Failure

ACE inhibitors, including Hipril, are a foundational treatment class for patients with heart failure (the heart's inability to pump blood efficiently). Long-term clinical trials have investigated the use of high-dose vs. low-dose regimens in this population, with analysis indicating that long-term high-dose regimens were generally as well-tolerated and had comparable findings regarding all-cause mortality and hospitalization across the study group, including patients at high cardiovascular risk.

Combination Therapy and Safety Profile

Hipril is often co-administered with other treatments, such as diuretics or calcium channel blockers, which may have enhanced effects on lowering blood pressure. Observational data indicates that use of ACE inhibitors is generally more often prescribed as a first-line therapy for patients under 55 years old, although the benefits extend across various age groups for heart failure management. Common adverse events reported across the drug class include a persistent dry cough and, rarely, angioedema.

Key Studies & References ACE Inhibitors - StatPearls (General class data on indications and adverse effects)

Frequently Asked Questions (FAQ)

Common questions about Hipril (FAQ)


Q: Is Hipril used to treat or prevent heart attacks and strokes?

A: According to official product information, Hipril (Lisinopril) is approved to reduce the risk of death following an acute myocardial infarction (heart attack). The drug's use in managing high blood pressure is also associated with a reduction in the risk of cardiovascular events, including stroke.

Q: How long is Hipril typically prescribed for?

A: Regulatory documents indicate this medicine is intended for sustained, long-term therapeutic use for chronic conditions like high blood pressure and heart failure. The effects of the medicine are maintained during prolonged use as part of a patient's overall management plan.

Q: Is it safe to suddenly stop taking Hipril once my blood pressure is stable?

A: Official guidance indicates that abrupt discontinuation should not occur without consulting a healthcare provider first. While official information indicates that stopping suddenly has not been associated with a rapid increase in blood pressure compared to pre-treatment levels, medical guidance is still required.

Q: Are there any long-term safety concerns associated with taking Hipril?

A: The official labeling highlights warnings and precautions for conditions that require monitoring during continuous use. These include the potential risk of impaired renal function (kidney function), hyperkalemia (high potassium levels), and a rare risk of hepatic failure (severe liver failure). Official product information states that monitoring for signs of liver injury may be necessary during continuous use.

Q: Can Hipril affect sexual function or performance?

A: A decrease in libido (desire for sex) has been reported as an adverse reaction in clinical studies for this medication. If this or other changes are experienced, official labeling recommends discussing the symptoms with a healthcare professional.

Q: Is a metallic or altered sense of taste a known side effect?

A: Yes, a change in the perception of taste has been reported as a side effect in regulatory documents. This altered or unpleasant taste is clinically described as altered taste perception.

Q: Can taking Hipril cause blurred vision?

A: Vision changes, such as blurry vision, have been reported as a side effect in regulatory documents. This may sometimes be associated with a temporary drop in blood pressure (hypotension).

Q: What are the safety concerns when consuming alcohol with Hipril?

A: Official information indicates that alcohol may contribute to additive effects in lowering blood pressure when combined with Hipril. This is associated with an increased risk of side effects such as headache, dizziness, and fainting.

Q: Does Hipril interact with medications used to treat diabetes?

A: Yes, regulatory documents note that concomitant use with antidiabetic medicines, such as insulins or oral hypoglycemic agents, can increase the risk of hypoglycemia (low blood sugar).

Q: How quickly does Hipril start to lower blood pressure after taking the first pill?

A: The onset of blood pressure-lowering activity has been observed within one hour of the medicine's administration. The maximum or peak reduction in blood pressure is typically achieved around 6 hours after taking the tablet.

Q: Is Hipril safe for people with known liver disease?

A: The official labeling includes a warning for the rare risk of a severe syndrome that can lead to hepatic failure (liver failure). Official product information states that monitoring for signs of liver injury may be necessary.

Q: What is the difference between an ACE inhibitor and an ARB drug?

A: Hipril is an ACE inhibitor that blocks the enzyme that creates the blood-vessel tightening chemical, Angiotensin II. ARBs (Angiotensin Receptor Blockers) work differently by blocking the receptors where Angiotensin II acts, preventing its tightening effect.

Q: How does Hipril help prevent a stroke or heart attack?

A: The medicine works primarily by suppressing the Renin-Angiotensin-Aldosterone System (RAAS), which decreases the activity that tightens blood vessels. This effect helps manage high blood pressure, which is a major factor linked to cardiovascular events.

Q: What should I do if I experience severe vomiting or diarrhea while taking Hipril?

A: Severe vomiting or diarrhea can cause volume depletion (loss of fluids), which may increase the likelihood of experiencing low blood pressure and dizziness. The regulatory safety profile notes that medical advice is appropriate if volume depletion occurs.

Q: Does Hipril cause weight gain or weight loss?

A: While not a typical effect, unexplained weight loss is a reported symptom that may be associated with rare, severe effects like liver injury. Conversely, sudden or unexplained weight gain is a symptom associated with the condition of heart failure, which this medicine is approved to treat.

Q: Does Hipril affect my ability to drive or operate machinery?

A: Official patient counseling states that individuals should avoid driving or operating complex machinery until they understand the full effects of the medication. This is due to the risk of dizzy or fainting spells, especially when first starting treatment.

Q: Can Hipril cause problems with sleep or insomnia?

A: Side effects reported under the Nervous System/Psychiatric classification include both insomnia (difficulty sleeping) and somnolence (drowsiness) according to regulatory data.

Q: Why is Hipril sometimes prescribed to people who already have normal blood pressure?

A: The medicine is approved to treat heart failure and to reduce the risk of death after a heart attack, both of which are approved uses that may apply to patients who do not have high blood pressure.

Q: Can Hipril affect my mood or cause confusion?

A: Side effects reported under the Nervous System/Psychiatric classification include confusion and mood alterations, which can include depressive symptoms.

Q: Does Hipril interact with common flu or cold medicines?

A: Caution is required because some common cold and flu medicines contain ingredients, such as NSAIDs or CNS depressants, that can either reduce the medicine's effectiveness or increase the risk of side effects like dizziness or worsening kidney function.

Q: What is intestinal angioedema, and is it a possible risk with Hipril?

A: Intestinal angioedema is a severe swelling of the bowel wall that has been reported in patients taking this class of medicine. It presents with symptoms like severe abdominal pain (with or without nausea or vomiting).

Q: Is Hipril likely to be habit-forming or addictive?

A: Official documents confirm that Lisinopril is not a controlled substance and is not associated with the euphoria or 'high' of typically addictive drugs. It is not considered habit-forming.

Q: Can Hipril be taken if I am on dialysis?

A: Lisinopril can be removed by hemodialysis. Official guidance indicates that use in patients with severe kidney impairment or on dialysis requires careful dose management and monitoring by a healthcare professional.

Q: Why does my doctor want to monitor my blood test results while I'm taking Hipril?

A: Monitoring is required to check for possible increases in serum potassium and to periodically assess renal function (kidney function). This is because the risks of hyperkalemia (high potassium) and worsening kidney impairment can increase during therapy.

Q: Is it true that certain demographics may experience the cough side effect more frequently?

A: Regulatory documents note that the serious side effect of angioedema has been reported to occur more frequently in black patients versus nonblack patients. No specific racial frequency data is provided in the official labeling for the dry cough side effect itself.

How should Hipril be stored and disposed of?

Hipril (Lisinopril) tablets must be stored according to regulatory requirements to ensure stability. Controlled room temperature is required, specifically between 20 C to 25 C (68 F to 77 F). The medicine must be protected from moisture and excessive heat and should not be frozen. Always keep the tablets in the original, tightly closed container.

Storage and Child Safety

The product must be stored out of the reach and sight of children.

Official Disposal Rules

Unused or expired Hipril should be taken to a drug take-back program or pharmacy. If a take-back option is unavailable, the tablets may be disposed of in household trash only after being mixed with an undesirable substance (such as dirt) and placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hipril found in:

A-Z Index: